Ascendis Pharma A (ASND) Non-Interest Income (2020 - 2024)

Ascendis Pharma A has reported Non-Interest Income for 7 years, with the latest figure at $12.0 million in Q1 2026.

• Quarterly Non-Interest Income rose 142.93% year-over-year to $12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.9 million (up 290.25% YoY) and the FY2025 annual result came in at -$19.0 million, down 164.8% from the prior year.
• Non-Interest Income climbed to $12.0 million in Q1 2026 per ASND's latest filing, from -$1.5 million in the prior quarter.
• Over five years, Non-Interest Income peaked at $228.6 million in Q1 2023 and troughed at -$28.0 million in Q1 2025.
• A 5-year average of $38.3 million and a median of $12.0 million in 2026 frame the typical range for Non-Interest Income.
• The sharpest annual moves came in 2023 and 2025: Non-Interest Income surged 213.92% in 2023, then sank 295.71% in 2025.
• Over 5 years, Non-Interest Income stood at $57.1 million in 2022, then slumped by 82.09% to $10.2 million in 2023, then sank by 52.22% to $4.9 million in 2024, then plunged by 131.63% to -$1.5 million in 2025, then jumped by 876.36% to $12.0 million in 2026.
• According to Business Quant data, Non-Interest Income over the past three periods registered $12.0 million, -$1.5 million, and $8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.